Sign in or 

People just like you can add or edit the content on this site. If you want to try editing, but aren't ready to add to this site, try our demo area.
Read more about editing pages at Wetpaint Central.
)
Women who were given the drug, Zometa, as part of their initial treatment had greater tumor shrinkage and were less likely to need radical surgery, according to a preliminary study reported yestersday at a cancer conference in Texas. | ||||||||
| . | ||||||||
In June, doctors were stunned when a big study found that Zometa given to prevent bone loss caused by certain cancer treatments also greatly cut the risk that cancer would recur in women who developed the disease before menopause. Cancer specialists are eagerly awaiting the final results of a second, ongoing study testing Zometa in 3,360 women who had breast cancer after menopause a much more common situation. Its leaders gave a mini-report Thursday on 205 participants who had chemotherapy to try to shrink their tumors before surgery. Those given infusions of Zometa along with chemo had a third more tumor shrinkage and as a result, were less likely to need their whole breast removed versus just the lump, said study leader Dr Robert Coleman of the University of Sheffield in England. Eleven percent of Zometa takers had a complete response to treatment no evidence of cancer in their breasts or lymph nodes versus 6 percent of women given chemo alone. Partial studies like this are not enough to change practice, but these results are surprising and deserve further testing, said Dr Eric Winer of the Dana-Farber Cancer Center in Boston. Such significant benefits from the bone drug before surgery is not something I would have expected, he said. | ||||||||
|
Sarnath |
Latest page update: made by Sarnath
, Dec 12 2008, 2:16 AM EST
(about this update
About This Update
No content added or deleted. - complete history) |
|
More Info: links to this page
|